White Paper on Hydroxychloroquine 2021
Hydroxychloroquine, Ivermectin, Vitamin D, Zinc and Azithromycin are among the handful of COVID-19 treatments that have been heavily studied as potential candidates that might influence the outcome in the prevention and management of COVID-19.
Some people may reference the Skipper study, an outpatient HCQ early treatment trial that concluded that “hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.” I know a few things about that particular study because I was one of the “private donors” who funded it. The summary means that the study was underpowered, not that the drug didn’t work. Indeed, if you look at each metric they looked at, the cohort who got the HCQ always did better. See this analysis for details. There is much more to this study that will come out later that will show that HCQ works even better than the 51.7% drop in hospitalization rate reported in the paper.
Hydroxychloroquine, Zinc and Azithromycin - AAPS (Association of American Physicians and Surgeons) Guidelines
|Figure Reprinted from The American Journal of Medicine DOI: 10.1016/j.amjmed.2020.07.003, McCullough P, et al Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection 2020|
Low Risk COVID-19 patients
- Quercetin oral 500 mg twice a day.
- Vitamin C 3000 mg
- Vitamin D3 5000 IU
- Zinc sulphate 220 mg
High Risk COVID-19 patients
- Hydroxychloroquine (HCQ) with azithromycin (AZM) or doxycycline OR
- Ivermectin with azithromycin (AZM) or doxycycline
- Inhaled Budesonide (example of a brand is Pulmicort, from AstraZeneca)
A New Study Shows, Again, That Hydroxychloroquine and Azithromycin Work
A fascinating new study posted to the medRxiv* (May 31, 2021) preprint server (not peer-reviewed), suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of
Using computational modeling, the use of weight-adjusted HCQ and AZM appears to be associated with a more than 100% increase in survival, without a clear correlation with ECG abnormalities.
Most importantly, this is the first clinical study to demonstrate the remarkable benefit of using cumulative doses of HCQ>3g/AZM>1g, compared to those not treated with this combination.
In this startling study, the investigators carefully re-examined the data, showing that among critically ill COVID-19 patients on IMV (invasive mechanical ventilation), less than 4% “walk out of hospital.” In contrast, the survival benefit of combined HCQ/AZM at a cumulative dosage of >80 mg/kg and >1g, respectively, is shown to be both clear and significant.
The safety at such doses is obvious, since survival is increased by almost 130% in this very high-risk population. Moreover, it appears that AZM (azithromycin) is an important component of this therapy in terms of mortality reduction.
Nebulized Hydroxychloroquine for COVID-19 Treatment: 80x Improvement in Breathing
Considering the unique pharmacokinetics of HCQ, oral HCQ might take 5–10 days to achieve adequate plasma and lung concentrations.
Dr Zelenko, published a white paper on nebulised hydroxychloroquine that resulted in an 80x improvement in time and efficiency when compared to HCQ tablet (400-600 mg per day) combination therapy or Ivermectin combination therapy.
Nebulized hydroxychloroquine as 150 mg HCQ in 6 ml (25 mg/ml) of isotonic sterile solution within the first five (5) days of COVID-19 symptoms (“Nebu HCQ”) has resulted in immediate improvement (<1 hour after use) in breathing in COVID-19 infected patients. Nebulized HCQ served as a rescue medication with an 80x improvement in time and efficiency when compared to HCQ tablet (400-600 mg per day) combination therapy or Ivermectin combination therapy. No adverse events were reported outside of a bitter taste that quickly subsided.
|Effect of QCT, EGCG, and CQ on the uptake of zinc cations by liposomes. Zinc-dependent fluorescence emission of FluoZin-3 encapsulated within liposomes treated with zinc cations, polyphenols, and CQ (J Agric Food Chem. 2014).|
“Zinc is involved in numerous aspects of cellular metabolism. It is required for the catalytic activity of approximately 100 enzymes and it plays a role in immune function, protein synthesis, wound healing, DNA synthesis, and cell division. Zinc also supports normal growth and development during pregnancy, childhood, and adolescence and is required for proper sense of taste and smell.”
Chelated zinc is a general form of supplementary zinc in which the zinc is chelated — or bound — to a compound to make it easier for the body to absorb. Zinc picolinate or zinc gluconate are formed when zinc is chelated to picolinic acid or gluconic acid, so the main difference between zinc gluconate and picolinate is what compound it is bound to.